Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) is partnering up with psilocybin patient advocate Thomas Hartle and his charity to release a psilocybin product made for patients.
On Tuesday, the Canadian psychedelics company announced the partnership with Hartle in commemoration of the two-year anniversary of Hartle being one of Canada’s first applicants to be approved to use psilocybin for medical purposes. The company will donate proceeds of sales directly to Hartle’s charity for facilitating patient access to psilocybin-assisted therapy.
The company and Hartle will host a virtual press conference scheduled for Wednesday at 1 pm where the details of the partnership and the new product will be discussed.
“Honestly, until I started receiving my psilocybin-assisted therapy treatments two years ago, I wasn’t sure if I could handle the daily stress of knowing that I was dying,” said Hartle.
“Having a therapeutic psilocybin product made in my honour, which I had never considered as a possibility, gives me pause to reflect on how many have lost their battles before ever experiencing the amazing benefits of psilocybin therapy.”
“I am excited to be partnering with Optimi to provide that opportunity to the people who need it most, with the hope that they will receive the same life-restoring gift that I have experienced.”
“Honouring Thomas’s incredible optimism and appreciation for life with his own natural, Canadian-grown psilocybin product is something we will cherish as a company forever,” said Bill Ciprick, CEO of Optimi Health.
“We share Thomas’s energy and passion for creating the perfect psilocybin experience, and we look forward to providing a vital service to Special Access Program patients while further demonstrating to regulators that psychedelic-assisted therapies can be integrated into our existing healthcare framework.”